# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benjamin Franklin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN004-SYN
- Date: 2026-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lydia Penhallow, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review four weeks after stone removal and prostate resection. **S**

## History of present illness

Mr. Franklin returns four weeks after transurethral laser cystolitholapaxy and resection of the prostate. The catheter came out on the second day after surgery. His stream is strong, he gets up once at night, and he has had no pain or blood in the urine for two weeks. Stone analysis showed pure uric acid. He has had no gout flare on allopurinol 200 mg and colchicine. The planned urate check two to five weeks after the dose increase was not done, because his surgery fell in that window. He completed a 24-hour urine collection yesterday. He drinks about 1.5 L a day and finds it hard to drink more. Tamsulosin was stopped at surgery. **S**

| Element | Detail |
|---|---|
| Surgery | Cystolitholapaxy and transurethral resection four weeks ago; uncomplicated |
| Stone analysis | 100 percent uric acid |
| Urinary symptoms | Strong stream, nocturia once, no pain or blood for two weeks |
| Gout | No flare on allopurinol 200 mg and colchicine |
| Fluids | About 1.5 L a day |
| Medicines stopped | Tamsulosin at surgery |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Genitourinary | Negative | No dysuria, hematuria, or incontinence; nocturia once |
| Musculoskeletal | Negative | No joint pain; no muscle aches on atorvastatin |
| Constitutional | Negative | No fever since surgery |

3 systems reviewed. **S**

## Current medications

- Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Allopurinol 300 mg oral tablet, one tablet by mouth daily **S**
- Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with meals **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/78 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 94.6 kg; BMI 30.9 kg/m². All vital signs are synthetic.

Serum urate: 6.4 mg/dL; Sodium: 140 mmol/L; Potassium: 4.5 mmol/L; Bicarbonate (total CO2): 23 mmol/L; BUN: 20 mg/dL; Creatinine: 1.31 mg/dL; eGFR: 56 mL/min/1.73 m² (low); Glucose: 95 mg/dL; Urine pH: 5.3 [pH]; Urine red cells: 1 /[HPF]; 24-hour urine volume: 1.45 L/(24.h) (low); 24-hour urine uric acid: 840 mg/(24.h) (high); 24-hour urine citrate: 410 mg/(24.h); 24-hour urine calcium: 180 mg/(24.h); Post-void residual volume by bladder ultrasound: 35 mL; IPSS: 6. All results are synthetic.

## Change since baseline

- Serum urate: 9.1 mg/dL (high) at baseline, 6.4 mg/dL at this visit **S**
- Sodium: 140 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Bicarbonate (total CO2): 25 mmol/L at baseline, 23 mmol/L at this visit **S**
- BUN: 22 mg/dL at baseline, 20 mg/dL at this visit **S**
- Creatinine: 1.36 mg/dL (high) at baseline, 1.31 mg/dL at this visit **S**
- eGFR: 54 mL/min/1.73 m² (low) at baseline, 56 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 98 mg/dL at baseline, 95 mg/dL at this visit **S**
- Urine pH: 5.2 [pH] at baseline, 5.3 [pH] at this visit **S**
- Urine red cells: 12 /[HPF] (high) at baseline, 1 /[HPF] at this visit **S**
- IPSS: 16 at baseline, 6 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Abdomen | No suprapubic tenderness; bladder not palpable |
| Joints | No synovitis or tophi |
| Cardiovascular | Regular rhythm; no edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Uric acid bladder stone, removed** (N21.0). Stone-free, with the obstruction relieved. The 24-hour urine shows the main risks for another uric acid stone: low urine volume (1.45 L), high uric acid excretion (840 mg a day), and acidic urine (pH 5.3). Citrate (410 mg a day) and calcium (180 mg a day) are normal. Red cells in the urine have cleared (1 per high-power field), so no further hematuria imaging is needed. **S**
   - Start potassium citrate 10 mEq twice daily with meals, aiming for a urine pH of 6.0 to 6.5.
   - Raise fluids to make at least 2.5 L of urine a day; a measuring jug at home.
   - Potassium check in 2 to 4 weeks, because he also takes losartan and has chronic kidney disease.
2. **Gout, titrating** (M1A.0710). Serum urate 6.4 mg/dL on allopurinol 200 mg, still above the target of below 6. **S**
   - Increase allopurinol to 300 mg daily.
   - Continue colchicine prophylaxis.
   - Serum urate in 2 to 5 weeks.
3. **Benign prostatic hyperplasia after resection** (N40.1). IPSS 6 and residual 35 mL, down from 16 and 160 mL; pathology benign. **S**
   - Reassess IPSS and residual at three and six months after surgery.
4. **Chronic kidney disease G3a A1** (N18.31). Creatinine 1.31 mg/dL, eGFR 56, potassium 4.5 mmol/L; stable after surgery. **S**
   - Continue losartan and atorvastatin.
5. **Hypertension** (I10). 132/78 mmHg; home average 132/78. **S**
   - Continue losartan; recheck at the next review.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum urate | Every 2 to 5 weeks while titrating; every 6 months once at target | Completed today | 6.4 mg/dL on allopurinol 200 mg; dose increased to 300 mg |
| Laboratory | Serum urate 2 to 5 weeks after raising allopurinol to 200 mg | Once after each dose change | Deferred | Not drawn in the window, a deviation from the protocol; the surgery fell in that period and the check was not rebooked. It is seven weeks today. No harm: no flare, and the dose is raised today. Corrective action: a standing urate order every four weeks until target |
| Medication safety | Flare prophylaxis and allopurinol tolerance | 3 to 6 months; every visit while titrating | Completed today | Colchicine week 11; no rash or muscle symptoms |
| Laboratory | Metabolic evaluation after a stone: 24-hour urine | Once, within 6 months of a stone event | Completed today | Volume 1.45 L, uric acid 840 mg/day, citrate 410 mg/day, calcium 180 mg/day |
| Laboratory | Urinalysis: urine pH and red cells | After stone treatment; with each change in alkalinization | Completed today | pH 5.3; red cells 1 per high-power field, cleared |
| Laboratory | Metabolic panel | With each eGFR draw; after starting potassium-affecting therapy | Completed today | Potassium 4.5 mmol/L, creatinine 1.31 mg/dL, eGFR 56 |
| Examination | Office and home blood pressure | Every visit | Completed today | 132/78 mmHg |
| Survey | IPSS | Every follow-up; 1, 3, 6, and 12 months after a procedure | Completed today | 6, down from 16 |
| Examination | Post-void residual after the procedure | Post-procedural follow-up | Completed today | 35 mL |
| Imaging | Imaging for hematuria | Only if hematuria persists after the stone is treated | Not indicated | Hematuria cleared and cystoscopy showed no tumor |
| Medication safety | Medication review for NSAIDs and dose adjustment | Every visit | Completed today | No NSAIDs; tamsulosin stopped at surgery |
| Self-management | Fluid intake | Every visit | Completed today | About 1.5 L a day, below the goal; measuring jug advised |

## Goal progress

- Serum urate below 6 mg/dL on allopurinol by the six-month review. In progress; target 2026-09-14. **S**
- Bladder stone removed and comfortable voiding with a normal post-void residual. Outcome by 2026-05-18: Stone removed; IPSS from 16 to 6; residual 35 mL. **S**
- No gout flare for six months after starting urate-lowering therapy. In progress; target 2026-09-14. **S**
- Blood pressure below 130/80 without dizziness. In progress; target 2026-09-14. **S**
- Urine output of at least 2.5 L a day and urine pH of 6.0 to 6.5. In progress; target 2026-09-14. **S**

## Medication changes

- Stopped: Allopurinol 100 mg oral tablet, two tablets (200 mg) by mouth daily **S**
- Started: Allopurinol 300 mg oral tablet, one tablet by mouth daily **S**
- Started: Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with meals **S**

## Guideline basis

- 2020 American College of Rheumatology Guideline for the Management of Gout (2020), American College of Rheumatology (Arthritis Care Res 2020;72(6):744-760)
- Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019), American Urological Association
- EAU Guidelines on Urolithiasis (including bladder stones) (2025), European Association of Urology
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment), American Urological Association
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026), Aether Forge

## Follow-up

- Potassium and serum urate in 2 to 5 weeks. Gout, stone, kidney, and blood pressure review in about four months. **S**
- Next scheduled visit 2026-09-14: gout, stone prevention, kidney, and blood pressure review at about six months. **S**
